TY - JOUR
AU - Reincke, Momsen
AU - von-Wardenburg, Niels-Oliver
AU - Homeyer, Marie Alice
AU - Kornau, Hans-Christian
AU - Spagni, Gregorio
AU - Li, Lucie Y
AU - Kreye, Jakob
AU - Sánchez-Sendín, Elisa
AU - Blumenau, Sonja
AU - Stappert, Dominik
AU - Radbruch, Helena
AU - Hauser, Anja E
AU - Künkele, Annette
AU - Edes, Inan
AU - Schmitz, Dietmar
AU - Prüss, Harald
TI - Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cells.
JO - Cell
VL - 186
IS - 23
SN - 0092-8674
CY - New York, NY
PB - Elsevier
M1 - DZNE-2023-01062
SP - 5084 - 5097.e18
PY - 2023
AB - Anti-NMDA receptor (NMDAR) autoantibodies cause NMDAR encephalitis, the most common autoimmune encephalitis, leading to psychosis, seizures, and autonomic dysfunction. Current treatments comprise broad immunosuppression or non-selective antibody removal. We developed NMDAR-specific chimeric autoantibody receptor (NMDAR-CAAR) T cells to selectively eliminate anti-NMDAR B cells and disease-causing autoantibodies. NMDAR-CAARs consist of an extracellular multi-subunit NMDAR autoantigen fused to intracellular 4-1BB/CD3ζ domains. NMDAR-CAAR T cells recognize a large panel of human patient-derived autoantibodies, release effector molecules, proliferate, and selectively kill antigen-specific target cell lines even in the presence of high autoantibody concentrations. In a passive transfer mouse model, NMDAR-CAAR T cells led to depletion of an anti-NMDAR B cell line and sustained reduction of autoantibody levels without notable off-target toxicity. Treatment of patients may reduce side effects, prevent relapses, and improve long-term prognosis. Our preclinical work paves the way for CAAR T cell phase I/II trials in NMDAR encephalitis and further autoantibody-mediated diseases.
KW - Animals
KW - Humans
KW - Mice
KW - Autoantibodies: metabolism
KW - Encephalitis: metabolism
KW - Encephalitis: therapy
KW - Receptors, N-Methyl-D-Aspartate
KW - T-Lymphocytes
KW - Autoimmune Diseases
KW - Disease Models, Animal
KW - CAAR T cell (Other)
KW - CAAR T cell (Other)
KW - CAAR T cell (Other)
KW - CAAR T cell (Other)
KW - CAAR T cell (Other)
KW - CAAR T cell (Other)
KW - NMDA receptor encephalitis (Other)
KW - T cells (Other)
KW - autoimmune encephalitis (Other)
KW - autoimmunity (Other)
KW - cell therapy (Other)
KW - chimeric autoantibody receptor (Other)
KW - Autoantibodies (NLM Chemicals)
KW - Receptors, N-Methyl-D-Aspartate (NLM Chemicals)
LB - PUB:(DE-HGF)16
C6 - pmid:37918394
DO - DOI:10.1016/j.cell.2023.10.001
UR - https://pub.dzne.de/record/265939
ER -